Buy Tesamorelin Canada (Tesamorelin — 20mg) 

Buy Tesamorelin Canada, a stabilized 44-amino-acid synthetic analog of human growth hormone-releasing hormone (GHRH) with an N-terminal trans-3-hexenoic acid modification. Studied for sustained pulsatile GH secretion, visceral fat metabolism, and IGF-1 axis research. 20mg lyophilized powder, 99%+ purity verified by Janoshik Analytical via HPLC and mass spectrometry.

• For laboratory research use only.

• Not for human or veterinary use.

• Not intended for diagnosis, treatment, cure, or prevention of any disease.

• Use only in controlled laboratory settings by qualified personnel following appropriate safety procedures.

Tesamorelin is a synthetic 44-amino-acid polypeptide analog of human growth hormone-releasing hormone (GHRH), originally developed by Theratechnologies Inc. of Canada. Its distinguishing feature is a trans-3-hexenoic acid group attached to the N-terminal tyrosine residue, which protects against DPP-IV enzymatic cleavage — the primary degradation pathway for native GHRH. Unlike CJC-1295 (No DAC) which modifies internal amino acids, Tesamorelin preserves the complete native GHRH sequence while adding a protective group. It has been the subject of extensive clinical research, including Phase 3 trials and regulatory review.

BENEFITS/Buy Tesamorelin Canada

• GHRH receptor activation — studied as a full-length GHRH analog with enhanced enzymatic stability

• Sustained GH pulsatility — investigated for physiological growth hormone release patterns

• Visceral fat metabolism — explored in clinical research for effects on regional adipose distribution

• IGF-1 axis research — studied for downstream effects on insulin-like growth factor production

• Clinical-grade data — one of the most extensively studied GHRH analogs in published literature

WHAT RESEARCHERS LOOK AT

• GH/IGF-1 axis stimulation and pulsatile GH release kinetics

• Visceral adipose tissue metabolism in clinical and preclinical models

• Lipid metabolism pathways and hepatic fat fraction changes

• Comparative pharmacokinetics vs. native GHRH (1-44) and sermorelin

• N-terminal acylation as a strategy for peptide stabilization

QUICK SPECS

• Form: Lyophilized peptide

• Net per vial: 20 mg

• Purity: ≥99% (HPLC verified)

• Identity: MS-verified (per COA)

• Storage: 2–8°C short-term, -20°C long-term, protect from light and moisture

• Reconstitution: Use bacteriostatic water (sold separately)

IDENTITY BASICS

• Sequence: 44-amino-acid GHRH analog with N-terminal trans-3-hexenoic acid modification

• Molecular Formula: C₂₂₁H₃₆₆N₇₂O₆₇S

• Molecular Weight: 5,135.9 g/mol

• CAS Number: 218949-48-5

• PubChem CID: 16137828

• Common Synonyms: ThGRF(1-44)NH₂, Egrifta (commercial name)